GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Evolent Health Inc (NYSE:EVH) » Definitions » Cash Conversion Cycle

Evolent Health (Evolent Health) Cash Conversion Cycle : 51.68 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Evolent Health Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Evolent Health's Days Sales Outstanding for the three months ended in Mar. 2024 was 62.38.
Evolent Health's Days Inventory for the three months ended in Mar. 2024 was 0.
Evolent Health's Days Payable for the three months ended in Mar. 2024 was 10.7.
Therefore, Evolent Health's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 51.68.


Evolent Health Cash Conversion Cycle Historical Data

The historical data trend for Evolent Health's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolent Health Cash Conversion Cycle Chart

Evolent Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.14 21.22 15.65 25.00 52.38

Evolent Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.30 42.54 50.84 58.96 51.68

Competitive Comparison of Evolent Health's Cash Conversion Cycle

For the Health Information Services subindustry, Evolent Health's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Evolent Health's Cash Conversion Cycle falls into.



Evolent Health Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Evolent Health's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=65.18+0-12.8
=52.38

Evolent Health's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=62.38+0-10.7
=51.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolent Health  (NYSE:EVH) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Evolent Health Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Evolent Health's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolent Health (Evolent Health) Business Description

Traded in Other Exchanges
Address
800 N. Glebe Road, Suite 500, Arlington, VA, USA, 22203
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's two reportable segments: EHS and Clinical Solutions. The Company's EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure and clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. It generates a majority of its revenue from Clinical Solutions segment.
Executives
Seth Blackley officer: President 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Daniel Joseph Mccarthy officer: PRESIDENT 800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Emily Ann Rafferty officer: Chief Operating Officer 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Toyin Ajayi director 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mary Bridget Duffy director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Diane Holder director 800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Richard M Jelinek director 40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035
Frank J Williams director, officer: Chief Executive Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
John Paul Johnson officer: Chief Financial Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Jonathan Weinberg officer: General Counsel 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Steve Tutewohl officer: Chief Operating Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Tunde Sotunde director 800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203
Kim Keck director 30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305